Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
The Source
TWSJ
Tech
It’s the Deadliest Room in the House—Especially for Seniors
TWSJ·23h ago·3 min read
World News
Drone Attacks on Russia’s Biggest Online Retailer Bring War Home to Middle Class
TWSJ·1h ago·3 min read
Business
The European Central Bank held interest rates steady, but investors expect it will push borrowing costs higher in the coming months
TWSJ·1h ago·3 min read
World News
Trump Says Iran Will Be Held Responsible for Future Houthi Attacks
TWSJ·55m ago·3 min read
Related
On this beat
Health
An outbreak of cyclosporiasis that’s sickened thousands shouldn’t prevent you from enjoying a Caesar salad—if you take the right precautions
TWSJ·46m ago·3 min read
Health
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
CNBC·3h ago·3 min read
Health
Ozempic face? Botox maker reports boost from ‘sagging face’ trend
CNBC·2h ago·3 min read
Health
A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
TNYT·4h ago·3 min read